Primary B-cell non-Hodgkin lymphoma of the parotid gland: An analysis based on the SEER database.

Primary malignant lymphoma of the parotid gland is a rare entity. The disease is often misdiagnosed, and its survival factors remain unclear. This study included patients diagnosed with primary B-cell non-Hodgkin lymphoma of the parotid gland from 1987 to 2016 in the surveillance, epidemiology, and end results program. Univariate survival analysis was conducted using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazards regression model. A competing risks regression model was applied to estimate the specific risks associated with parotid lymphoma mortality. A total of 1443 patients were identified. The overall survival of indolent primary B-cell lymphoma of the parotid gland was higher than that of aggressive lymphoma (hazard ratio 0.53, 95% confidence interval 0.44-0.64, P < .001), and older patients (≥70 years) exhibited inferior overall survival. Histological subtype and age are important prognostic factors in patients with primary B-cell non-Hodgkin lymphoma of the parotid gland.

Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.

Oral cancer accounts for 95% of all maxillofacial malignant neoplasm. Presently, surgery and radiation (with and without chemotherapy) are the major treatments for oral cancer; however it met with limited therapeutic outcome. Overcoming the multidrug resistance and finding new therapeutic agents for oral cancer treatment are some of the serious challenges. Small molecule, TH287 potently and selectively inhibits the MTH1 protein in cells and could act as a new chemotherapeutic agent. The study reports the successful loading and delivery of MTH1 inhibitor - TH287 and MDR1 siRNA in oral squamous cell carcinoma. Our results showed that HA-assembled mesoporous silica nanoparticles were effective in controlling the drug release and internalization in CAL27 cancer cells. Cytotoxicity and apoptosis assay showed that combination of TH287 + MDR1 siRNA was significantly more effective in inducing the anticancer effect compared to that of TH287 (MTH1 inhibitor) alone. SiTMSN and HA-siTMSN significantly reduced the tumor burden compared to that of untreated control and free TH287. The study strongly supports the fact that the HA-siTMSN plays dual of inhibiting the MDR1 function and enhancing the cell killing effect of TH287 in the cancer tissues. Overall, results suggest that the HA-siTMSN platform is a promising vector the systemic delivery of MDR1 siRNA/TH287 and combinational therapeutics could be a viable solution for treatment of cancer of oral cavity.